JP2009518400A - ベンジイミダゾール非水性組成物 - Google Patents
ベンジイミダゾール非水性組成物 Download PDFInfo
- Publication number
- JP2009518400A JP2009518400A JP2008544409A JP2008544409A JP2009518400A JP 2009518400 A JP2009518400 A JP 2009518400A JP 2008544409 A JP2008544409 A JP 2008544409A JP 2008544409 A JP2008544409 A JP 2008544409A JP 2009518400 A JP2009518400 A JP 2009518400A
- Authority
- JP
- Japan
- Prior art keywords
- benzimidazole
- composition
- composition according
- macrocyclic lactone
- triclabendazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims abstract description 23
- 150000002596 lactones Chemical class 0.000 claims abstract description 22
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims abstract description 15
- 229960004816 moxidectin Drugs 0.000 claims abstract description 15
- 229960000323 triclabendazole Drugs 0.000 claims abstract description 15
- 244000045947 parasite Species 0.000 claims abstract description 13
- 244000078703 ectoparasite Species 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- 206010061217 Infestation Diseases 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 208000015181 infectious disease Diseases 0.000 claims abstract description 5
- 230000000507 anthelmentic effect Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 19
- -1 alkylene glycol Chemical compound 0.000 claims description 13
- 239000005660 Abamectin Substances 0.000 claims description 11
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 claims description 5
- WCBVUETZRWGIJQ-UHFFFAOYSA-N 2-[[(methoxycarbonylamino)-(2-nitro-5-propylsulfanylanilino)methylidene]amino]ethanesulfonic acid Chemical compound CCCSC1=CC=C([N+]([O-])=O)C(NC(NC(=O)OC)=NCCS(O)(=O)=O)=C1 WCBVUETZRWGIJQ-UHFFFAOYSA-N 0.000 claims description 5
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 5
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 5
- BWCRYQGQPDBOAU-UHFFFAOYSA-N Milbemycin D Natural products C1CC(C)C(C(C)C)OC21OC(CC=C(C)CC(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 BWCRYQGQPDBOAU-UHFFFAOYSA-N 0.000 claims description 5
- RAOCRURYZCVHMG-UHFFFAOYSA-N N-(6-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)NC2=C1 RAOCRURYZCVHMG-UHFFFAOYSA-N 0.000 claims description 5
- VXTGHWHFYNYFFV-UHFFFAOYSA-N albendazole S-oxide Chemical compound CCCS(=O)C1=CC=C2NC(NC(=O)OC)=NC2=C1 VXTGHWHFYNYFFV-UHFFFAOYSA-N 0.000 claims description 5
- 229950010075 albendazole sulfoxide Drugs 0.000 claims description 5
- 229960003475 cambendazole Drugs 0.000 claims description 5
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 claims description 5
- 229960003997 doramectin Drugs 0.000 claims description 5
- 229960005473 fenbendazole Drugs 0.000 claims description 5
- 229960002418 ivermectin Drugs 0.000 claims description 5
- 229960003439 mebendazole Drugs 0.000 claims description 5
- BWCRYQGQPDBOAU-WZBVPYLGSA-N milbemycin D Chemical group C1C[C@H](C)[C@@H](C(C)C)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 BWCRYQGQPDBOAU-WZBVPYLGSA-N 0.000 claims description 5
- 229960004454 oxfendazole Drugs 0.000 claims description 5
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 claims description 5
- QZWHWHNCPFEXLL-UHFFFAOYSA-N propan-2-yl n-[2-(1,3-thiazol-4-yl)-3h-benzimidazol-5-yl]carbamate Chemical compound N1C2=CC(NC(=O)OC(C)C)=CC=C2N=C1C1=CSC=N1 QZWHWHNCPFEXLL-UHFFFAOYSA-N 0.000 claims description 5
- 229960004546 thiabendazole Drugs 0.000 claims description 5
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical group S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 claims description 5
- 239000004308 thiabendazole Substances 0.000 claims description 5
- 235000010296 thiabendazole Nutrition 0.000 claims description 5
- QGHREAKMXXNCOA-UHFFFAOYSA-N thiophanate-methyl Chemical compound COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC QGHREAKMXXNCOA-UHFFFAOYSA-N 0.000 claims description 5
- 241000283086 Equidae Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000282887 Suidae Species 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
- 238000003304 gavage Methods 0.000 claims description 2
- 239000008240 homogeneous mixture Substances 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 claims 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 244000079386 endoparasite Species 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 12
- 150000001556 benzimidazoles Chemical class 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229960002669 albendazole Drugs 0.000 description 4
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- HDDSHPAODJUKPD-UHFFFAOYSA-N fenbendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 HDDSHPAODJUKPD-UHFFFAOYSA-N 0.000 description 4
- OPXLLQIJSORQAM-UHFFFAOYSA-N mebendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(=O)C1=CC=CC=C1 OPXLLQIJSORQAM-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- 241000242711 Fasciola hepatica Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000006275 fascioliasis Diseases 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000283014 Dama Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 241000283011 Rangifer Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229950006716 netobimin Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明の他の目的および特徴は、以下の詳細な記載からより明らかになるだろう。
また、恒温動物における寄生虫感染症および寄生虫侵入の治療および制御方法、ならびに非水性経口獣医用組成物の製造方法を提供する。
プロピレングリコールジカプリレート/ジカプレートの一部を、PEG−35ヒマシ油と均質になるまで混ぜ合わせた。混合物を、ベンジルアルコール、ついで、モキシデクチンで処理し、溶液となるまで撹拌した。溶液をゆっくりとトリクラベンダゾールで処理し、溶液となるまで混ぜ合わせた。残りのプロピレングリコールジカプリレート/ジカプレートを加え、透明で均質な溶液が得られるまで混ぜ合わせた。
シュークロースモノオレアートを、ゆっくりとエタノールに加え、溶液となるまで混ぜ合わせた。モキシデクチンを加え、混合物を溶液となるまで撹拌した。PEG400の一部を加え、混合物を溶液が均質になるまで撹拌し、ついで、トリクラベンダゾールをゆっくりと加え、溶液となるまで撹拌を続けた。残りのPEG400を加え、得られた混合物を、透明で均質な溶液が得られるまで混ぜ合わせた。
試験組成物の血漿濃度の評価
この評価において、実施例1〜5で調製した試験組成物および慣用的なモキシデクチン/トリクラベンダゾール含有懸濁液を、ヒツジに経口投与した。血液サンプルを処理後29時間経過するまで採取し、トリクラベンダゾール代謝物およびモキシデクチンに関してアッセイした。試験組成物1〜5のアッセイ成分の血液濃度は、慣用的な懸濁組成物とほとんど同じであるか、あるいは上回った。
Claims (16)
- 1種またはそれ以上の界面活性剤、水混和性溶媒、任意に油、ならびに各々有効量のベンズイミダゾール駆虫化合物および大環状ラクトンを含む組成物。
- ベンズイミダゾールが、チアベンダゾール;カムベンダゾール;ペルベンダゾール;メベンダゾール;フェンベンダゾール;オクスフェンダゾール;オキシベンダゾール;アルベンダゾール;アルベンダゾールスルホキシド;メチルチオファネート;フェバンテル;ネトビミンまたはトリクラベンダゾールである、請求項1記載の組成物。
- ベンズイミダゾールがトリクラベンダゾールである、請求項1記載の組成物。
- 大環状ラクトンが、ミルベマイシンD;アベルメクチン;イベルメクチン;アベルメクチン;ドラメクチンまたはモキシデクチンである、請求項1〜3いずれか1項記載の組成物。
- 大環状ラクトンがモキシデクチンである、請求項1〜3いずれか1項記載の組成物。
- 水混和性溶媒が、アルキレングリコール;ポリアルキレングリコールもしくはアルコールまたはそれらの混合物である、請求項1〜5いずれか1項記載の組成物。
- 油が約10〜約70%w/v存在する、請求項1〜6いずれか1項記載の組成物。
- 油がプロピレングリコールジカプリレート/ジカプレートである、請求項1〜7いずれか1項記載の組成物。
- 界面活性剤が約2.5〜約60.0%w/vで存在する、請求項1〜8いずれか1項記載の組成物。
- 有効量が、約2〜約10%w/vのベンズイミダゾールおよび約0.01〜約2.0%w/vの大環状ラクトンである、請求項1〜9いずれか1項記載の組成物。
- 恒温動物における内部および外部寄生性感染症または寄生虫侵入の治療または制御方法であって、該動物に、請求項1〜10いずれか1項記載の組成物を経口投与することを含む方法。
- 組成物を強制飼養またはドレンチとして投与する、請求項11記載の方法。
- 動物がブタ;ウシ;ウマおよびヒツジから選択される、請求項11または請求項12記載の方法。
- 請求項1記載の組成物の製造方法であって、1種またはそれ以上の界面活性剤および任意に油を混合して、均一な混合物を得;該混合物に大環状ラクトンを混合して、溶液を形成し;該溶液をベンズイミダゾールおよび水混和性溶媒と混合することを含む方法。
- ベンズイミダゾールがトリクラベンダゾールである、請求項14記載の方法。
- 大環状ラクトンがモキシデクチンである、請求項14または請求項15記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74272405P | 2005-12-06 | 2005-12-06 | |
US60/742,724 | 2005-12-06 | ||
PCT/US2006/046197 WO2007067470A2 (en) | 2005-12-06 | 2006-12-04 | Benzimidazole non-aqueous compositions |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009518400A true JP2009518400A (ja) | 2009-05-07 |
JP2009518400A5 JP2009518400A5 (ja) | 2013-07-04 |
JP5342239B2 JP5342239B2 (ja) | 2013-11-13 |
Family
ID=37903547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008544409A Expired - Fee Related JP5342239B2 (ja) | 2005-12-06 | 2006-12-04 | ベンジイミダゾール非水性組成物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7687471B2 (ja) |
EP (1) | EP1957040B1 (ja) |
JP (1) | JP5342239B2 (ja) |
KR (1) | KR20080073700A (ja) |
AR (1) | AR057219A1 (ja) |
AU (1) | AU2006322120B2 (ja) |
BR (1) | BRPI0619620B1 (ja) |
CA (1) | CA2630458C (ja) |
DK (1) | DK1957040T3 (ja) |
ES (1) | ES2527120T3 (ja) |
NZ (1) | NZ567991A (ja) |
PT (1) | PT1957040E (ja) |
TW (1) | TWI433691B (ja) |
WO (1) | WO2007067470A2 (ja) |
ZA (1) | ZA200804915B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008015764A (es) | 2006-06-14 | 2009-01-07 | Intervet Int Bv | Suspension que comprende carbamato de bencimidazol y polisorbato. |
TWI556741B (zh) | 2007-08-17 | 2016-11-11 | 英特威特國際股份有限公司 | 異唑啉組成物及其作為抗寄生蟲藥上的應用 |
ES2617672T3 (es) * | 2008-10-08 | 2017-06-19 | Zoetis Services Llc | Composiciones antihelmínticas de bencimidazol |
WO2010126857A1 (en) * | 2009-04-28 | 2010-11-04 | Wyeth Llc | Parasiticidal combinations of macrocyclic lactones and polyether antibiotics |
MX369832B (es) * | 2012-05-18 | 2019-11-22 | Luoda Pharma Ltd | Formulaciones líquidas que comprenden pimobendan y propilenglicol para el tratamiento de hipertensión y/o enfermedades cardiacas. |
BR102013031277B1 (pt) * | 2013-12-05 | 2018-10-02 | Ouro Fino Participacoes E Empreendimentos S A | processo para preparar uma suspensão anti-helmíntica e suspensão anti-helmíntica injetável |
CN112006981B (zh) * | 2020-07-30 | 2023-01-10 | 瑞普(天津)生物药业有限公司 | 一种长效复方驱虫药物液体制剂及其制备方法与应用 |
BR102020021181A2 (pt) * | 2020-10-16 | 2022-04-26 | Ipanema Industria De Produtos Veterinarios Ltda | Microssuspensão contra parasitas e método para sua obtenção |
CN114304161B (zh) * | 2021-11-25 | 2024-08-09 | 兰州大学 | 三氯苯达唑在防治农业病原菌中的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000074489A1 (en) * | 1999-06-04 | 2000-12-14 | Nufarm Limited | Stable biocidal compositions |
WO2001005232A1 (en) * | 1999-07-19 | 2001-01-25 | Nufarm Limited | Stable biocidal compositions |
WO2004043445A1 (en) * | 2002-11-11 | 2004-05-27 | Schering-Plough Ltd. | Topical parasiticide formulations and methods of treatment |
WO2005074914A1 (en) * | 2004-02-03 | 2005-08-18 | Wyeth | Anthelmintic composition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ266408A (en) * | 1993-05-26 | 1997-09-22 | Commw Scient Ind Res Org | Antiparasitic, oral particulate composition for ruminants |
FR2755824B1 (fr) * | 1996-11-19 | 1999-01-08 | Virbac Sa | Formulation galenique des benzimidazoles a usage topique, son procede de preparation et ses utilisations |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
CN1435176A (zh) | 2002-01-29 | 2003-08-13 | 王玉万 | 以表面活性剂为基础的含三氯苯哒唑的新制剂 |
-
2006
- 2006-12-04 ES ES06838906.3T patent/ES2527120T3/es active Active
- 2006-12-04 NZ NZ567991A patent/NZ567991A/en unknown
- 2006-12-04 JP JP2008544409A patent/JP5342239B2/ja not_active Expired - Fee Related
- 2006-12-04 EP EP06838906.3A patent/EP1957040B1/en active Active
- 2006-12-04 BR BRPI0619620-9A patent/BRPI0619620B1/pt active IP Right Grant
- 2006-12-04 AU AU2006322120A patent/AU2006322120B2/en active Active
- 2006-12-04 AR ARP060105354A patent/AR057219A1/es not_active Application Discontinuation
- 2006-12-04 KR KR1020087009605A patent/KR20080073700A/ko not_active Application Discontinuation
- 2006-12-04 PT PT68389063T patent/PT1957040E/pt unknown
- 2006-12-04 DK DK06838906.3T patent/DK1957040T3/en active
- 2006-12-04 WO PCT/US2006/046197 patent/WO2007067470A2/en active Application Filing
- 2006-12-04 CA CA2630458A patent/CA2630458C/en not_active Expired - Fee Related
- 2006-12-05 US US11/634,027 patent/US7687471B2/en not_active Expired - Fee Related
- 2006-12-06 TW TW095145431A patent/TWI433691B/zh not_active IP Right Cessation
-
2008
- 2008-06-05 ZA ZA200804915A patent/ZA200804915B/xx unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000074489A1 (en) * | 1999-06-04 | 2000-12-14 | Nufarm Limited | Stable biocidal compositions |
WO2001005232A1 (en) * | 1999-07-19 | 2001-01-25 | Nufarm Limited | Stable biocidal compositions |
WO2004043445A1 (en) * | 2002-11-11 | 2004-05-27 | Schering-Plough Ltd. | Topical parasiticide formulations and methods of treatment |
WO2005074914A1 (en) * | 2004-02-03 | 2005-08-18 | Wyeth | Anthelmintic composition |
Also Published As
Publication number | Publication date |
---|---|
CA2630458C (en) | 2014-10-28 |
DK1957040T3 (en) | 2014-12-08 |
EP1957040B1 (en) | 2014-11-19 |
NZ567991A (en) | 2010-07-30 |
US7687471B2 (en) | 2010-03-30 |
PT1957040E (pt) | 2015-01-14 |
WO2007067470A2 (en) | 2007-06-14 |
BRPI0619620B1 (pt) | 2020-11-10 |
AR057219A1 (es) | 2007-11-21 |
AU2006322120A1 (en) | 2007-06-14 |
TW200800293A (en) | 2008-01-01 |
AU2006322120B2 (en) | 2012-07-26 |
BRPI0619620A2 (pt) | 2011-10-04 |
KR20080073700A (ko) | 2008-08-11 |
TWI433691B (zh) | 2014-04-11 |
WO2007067470A3 (en) | 2007-10-18 |
CA2630458A1 (en) | 2007-06-14 |
ZA200804915B (en) | 2010-08-25 |
EP1957040A2 (en) | 2008-08-20 |
ES2527120T3 (es) | 2015-01-20 |
US20070128239A1 (en) | 2007-06-07 |
JP5342239B2 (ja) | 2013-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5342239B2 (ja) | ベンジイミダゾール非水性組成物 | |
US20090036458A1 (en) | Endoparasiticidal topical compositions | |
US20060121072A1 (en) | Topical parasiticide formulations and methods of treatment | |
CA2673193C (en) | Homogeneous paste and gel formulations | |
AU2009245834B2 (en) | Benzimidazole anthelmintic compositions | |
JP4677405B2 (ja) | 駆虫組成物 | |
AU2006203354B2 (en) | Topical formulation | |
EP1259244B1 (en) | Veterinary compositions for the treatment of parasitic diseases | |
AU2003275779A1 (en) | Topical parasiticide formulations and methods of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091203 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20101019 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120820 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20121121 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20130125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130212 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130509 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20130510 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20130516 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130711 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130809 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |